IDEAYA Biosciences (IDYA) Retained Earnings (2018 - 2026)
IDEAYA Biosciences (IDYA) reported Retained Earnings of -$835.1 million for Q1 2026, down 52787.7% on a YoY basis from N/an in Q1 2025, and down 13.38% sequentially from -$736.5 million in Q4 2025.
IDEAYA Biosciences (IDYA) Retained Earnings (2018 - 2026) Analysis & Trends
IDEAYA Biosciences (IDYA) has 9 years of Retained Earnings data on file, last reported at -$835.1 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 52787.7% year-over-year to -$835.1 million; the trailing twelve-month figure through Mar 2026 stood at -$835.1 million (down 52787.7% YoY), and the FY2025 full-year result was -$736.5 million, down 18.25% from the prior year.
- Retained Earnings retreated to -$835.1 million in Q1 2026, from -$736.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1.6 million in Q1 2025 to a low of -$835.1 million in Q1 2026.
- A 5-year average of -$283.7 million and a median of -$259.0 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings tumbled 65570.53% in 2024 and surged 207.42% in 2025, its largest moves.
- Tracing IDYA's Retained Earnings over 5 years: stood at -$2.9 million in 2022, then sank by 12033.89% to -$348.4 million in 2023, then plunged by 78.79% to -$622.8 million in 2024, then decreased by 18.25% to -$736.5 million in 2025, then retreated by 13.38% to -$835.1 million in 2026.
- Business Quant data shows IDYA's Retained Earnings at -$835.1 million in Q1 2026, -$736.5 million in Q4 2025, and -$653.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | IDEAYA Biosciences | 3.21 Bn | 2.54 Bn | - | -835.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -835.10 Mn |
| Dec 31, 2025 | -736.54 Mn |
| Sep 30, 2025 | -653.30 Mn |
| Jun 30, 2025 | 1.52 Mn |
| Mar 31, 2025 | 1.59 Mn |
| Dec 31, 2024 | -622.84 Mn |
| Sep 30, 2024 | -492.53 Mn |
| Jun 30, 2024 | -1.42 Mn |
| Mar 31, 2024 | -387.94 Mn |
| Dec 31, 2023 | -348.36 Mn |
| Sep 30, 2023 | -750,000.00 |
| Jun 30, 2023 | -286.97 Mn |
| Mar 31, 2023 | -259.04 Mn |
| Dec 31, 2022 | -2.87 Mn |
| Sep 30, 2022 | -4.00 Mn |
| Jun 30, 2022 | -3.63 Mn |
| Mar 31, 2022 | -190.76 Mn |
| Dec 31, 2021 | -712,000.00 |
| Sep 30, 2021 | -158.50 Mn |
| Jun 30, 2021 | -147.00 Mn |